The Next Generation of CRISPR-Cas Technologies and Applications

Overview

Journal Nat Rev Mol Cell Biol

Specialties Cell Biology
Molecular Biology

Date 2019 Jun 1

PMID 31147612

Citations 572

Authors

Adrian Pickar-Oliver

Charles A Gersbach

Affiliations

Soon will be listed here.

Abstract

The prokaryote-derived CRISPR-Cas genome editing systems have transformed our ability to manipulate, detect, image and annotate specific DNA and RNA sequences in living cells of diverse species. The ease of use and robustness of this technology have revolutionized genome editing for research ranging from fundamental science to translational medicine. Initial successes have inspired efforts to discover new systems for targeting and manipulating nucleic acids, including those from Cas9, Cas12, Cascade and Cas13 orthologues. Genome editing by CRISPR-Cas can utilize non-homologous end joining and homology-directed repair for DNA repair, as well as single-base editing enzymes. In addition to targeting DNA, CRISPR-Cas-based RNA-targeting tools are being developed for research, medicine and diagnostics. Nuclease-inactive and RNA-targeting Cas proteins have been fused to a plethora of effector proteins to regulate gene expression, epigenetic modifications and chromatin interactions. Collectively, the new advances are considerably improving our understanding of biological processes and are propelling CRISPR-Cas-based tools towards clinical use in gene and cell therapies.

Citing Articles

Epigenetic regulation of iron metabolism and ferroptosis in Parkinson's disease: Identifying novel epigenetic targets.

Gao X, Ding J, Xie J, Xu H Acta Pharmacol Sin. 2025; .

PMID: 40069488 DOI: 10.1038/s41401-025-01499-6.

RNA-Based Therapies in Kidney Diseases.

Hu L, Jin T, Zhang N, Ding J, Li L J Inflamm Res. 2025; 18:3143-3160.

PMID: 40059951 PMC: 11890006. DOI: 10.2147/JIR.S505252.

Molecular insights and rational engineering of a compact CRISPR-Cas effector Cas12h1 with a broad-spectrum PAM.

Zheng W, Li H, Liu M, Wei Y, Liu B, Li Z Signal Transduct Target Ther. 2025; 10(1):66.

PMID: 39955288 PMC: 11830025. DOI: 10.1038/s41392-025-02147-5.

Taming the wild: domesticating untapped northern fruit tree and shrub resources in the era of high-throughput technologies.

Gelinas Belanger J AoB Plants. 2025; 17(1):plae074.

PMID: 39886049 PMC: 11780843. DOI: 10.1093/aobpla/plae074.

Direct repeat region 3' end modifications regulate Cas12a activity and expand its applications.

Zhang W, Zhong Y, Wang J, Zou G, Chen Q, Liu C Nucleic Acids Res. 2025; 53(3).

PMID: 39883010 PMC: 11780881. DOI: 10.1093/nar/gkaf040.

References

Nishikura K . Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem. 2010; 79:321-49. PMC: 2953425. DOI: 10.1146/annurev-biochem-060208-105251. View

Morgan S, Mariano N, Bermudez A, Arruda N, Wu F, Luo Y . Manipulation of nuclear architecture through CRISPR-mediated chromosomal looping. Nat Commun. 2017; 8:15993. PMC: 5511349. DOI: 10.1038/ncomms15993. View

Vierstra J, Reik A, Chang K, Stehling-Sun S, Zhou Y, Hinkley S . Functional footprinting of regulatory DNA. Nat Methods. 2015; 12(10):927-30. PMC: 5381659. DOI: 10.1038/nmeth.3554. View

Ding Q, Strong A, Patel K, Ng S, Gosis B, Regan S . Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. 2014; 115(5):488-92. PMC: 4134749. DOI: 10.1161/CIRCRESAHA.115.304351. View

Yeo N, Chavez A, Lance-Byrne A, Chan Y, Menn D, Milanova D . An enhanced CRISPR repressor for targeted mammalian gene regulation. Nat Methods. 2018; 15(8):611-616. PMC: 6129399. DOI: 10.1038/s41592-018-0048-5. View

Korkmaz G, Lopes R, Ugalde A, Nevedomskaya E, Han R, Myacheva K . Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9. Nat Biotechnol. 2016; 34(2):192-8. DOI: 10.1038/nbt.3450. View

Black J, Adler A, Wang H, DIppolito A, Hutchinson H, Reddy T . Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells. Cell Stem Cell. 2016; 19(3):406-14. PMC: 5010447. DOI: 10.1016/j.stem.2016.07.001. View

Fujita T, Fujii H . Efficient isolation of specific genomic regions and identification of associated proteins by engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP) using CRISPR. Biochem Biophys Res Commun. 2013; 439(1):132-6. DOI: 10.1016/j.bbrc.2013.08.013. View

Maeder M, Stefanidakis M, Wilson C, Baral R, Barrera L, Bounoutas G . Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019; 25(2):229-233. DOI: 10.1038/s41591-018-0327-9. View

10.

Maeder M, Linder S, Cascio V, Fu Y, Ho Q, Joung J . CRISPR RNA-guided activation of endogenous human genes. Nat Methods. 2013; 10(10):977-9. PMC: 3794058. DOI: 10.1038/nmeth.2598. View

11.

Nelson C, Wu Y, Gemberling M, Oliver M, Waller M, Bohning J . Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med. 2019; 25(3):427-432. PMC: 6455975. DOI: 10.1038/s41591-019-0344-3. View

12.

Gao L, Cox D, Yan W, Manteiga J, Schneider M, Yamano T . Engineered Cpf1 variants with altered PAM specificities. Nat Biotechnol. 2017; 35(8):789-792. PMC: 5548640. DOI: 10.1038/nbt.3900. View

13.

Dugar G, Leenay R, Eisenbart S, Bischler T, Aul B, Beisel C . CRISPR RNA-Dependent Binding and Cleavage of Endogenous RNAs by the Campylobacter jejuni Cas9. Mol Cell. 2018; 69(5):893-905.e7. PMC: 5859949. DOI: 10.1016/j.molcel.2018.01.032. View

14.

Perez-Pinera P, Kocak D, Vockley C, Adler A, Kabadi A, Polstein L . RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods. 2013; 10(10):973-6. PMC: 3911785. DOI: 10.1038/nmeth.2600. View

15.

Hou Z, Zhang Y, Propson N, Howden S, Chu L, Sontheimer E . Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci U S A. 2013; 110(39):15644-9. PMC: 3785731. DOI: 10.1073/pnas.1313587110. View

16.

Kleinstiver B, Pattanayak V, Prew M, Tsai S, Nguyen N, Zheng Z . High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016; 529(7587):490-5. PMC: 4851738. DOI: 10.1038/nature16526. View

17.

McKenna A, Findlay G, Gagnon J, Horwitz M, Schier A, Shendure J . Whole-organism lineage tracing by combinatorial and cumulative genome editing. Science. 2016; 353(6298):aaf7907. PMC: 4967023. DOI: 10.1126/science.aaf7907. View

18.

Liu Y, Cao Z, Wang Y, Guo Y, Xu P, Yuan P . Genome-wide screening for functional long noncoding RNAs in human cells by Cas9 targeting of splice sites. Nat Biotechnol. 2018; . DOI: 10.1038/nbt.4283. View

19.

Chen Y, Cao J, Xiong M, Petersen A, Dong Y, Tao Y . Engineering Human Stem Cell Lines with Inducible Gene Knockout using CRISPR/Cas9. Cell Stem Cell. 2015; 17(2):233-44. PMC: 4530040. DOI: 10.1016/j.stem.2015.06.001. View

20.

Kleinstiver B, Sousa A, Walton R, Tak Y, Hsu J, Clement K . Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nat Biotechnol. 2019; 37(3):276-282. PMC: 6401248. DOI: 10.1038/s41587-018-0011-0. View